Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Ethan Bernard Ludmir

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5472-5344; OpenAlex author ID A5026186757, A5139546905. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 1, last author 3)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
90
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers, 2 trials · 2025: 5 papers · 2026: 4 papers

Papers 20

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Last author DOI 10.1016/s1470-2045(25)00666-7↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  4. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  5. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s12029-024-01145-0↗
  6. Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer. Last author DOI 10.1016/j.semradonc.2025.07.004↗
  7. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  8. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  9. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  10. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  11. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  12. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  13. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  14. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. First author DOI 10.1016/j.ctro.2021.12.012↗
  15. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1016/j.ctro.2022.04.007↗
  16. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  17. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
  18. Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. Co-author DOI 10.1016/j.currproblcancer.2020.100607↗
  19. Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. Co-author DOI 10.3390/cancers12092487↗
  20. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.07.02↗

Trials 2

  1. A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) Principal investigator NCT06367972↗
  2. Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial Principal investigator NCT06593431↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eugene Jon Koay · 13 shared papers, 2021–2026 · strength 2.00
  2. Matthew H. G. Katz · 11 shared papers, 2021–2026 · strength 1.63
  3. Ching-Wei David Tzeng · 9 shared papers, 2022–2025 · strength 1.42
  4. Robert A. Wolff · 9 shared papers, 2022–2026 · strength 1.37
  5. Shubham Pant · 8 shared papers, 2022–2026 · strength 1.30
  6. Albert C. Koong · 8 shared papers, 2021–2025 · strength 1.18
  7. Cullen M. Taniguchi · 9 shared papers, 2020–2024 · strength 1.15
  8. Michael James Overman · 6 shared papers, 2022–2026 · strength 0.93
  9. Naruhiko Ikoma · 6 shared papers, 2022–2026 · strength 0.89
  10. Anirban Maitra · 5 shared papers, 2022–2026 · strength 0.85
  11. Brandon George Smaglo · 5 shared papers, 2023–2026 · strength 0.85
  12. Alexander Dean Sherry · 3 shared papers, 2024–2026 · strength 0.81
  13. Todd Anthony Aguilera · 3 shared papers, 2023–2025 · strength 0.78
  14. Michael P. Kim · 5 shared papers, 2022–2025 · strength 0.70
  15. Grace L. Smith · 5 shared papers, 2022–2024 · strength 0.67
  16. Jason A. Willis · 4 shared papers, 2024–2026 · strength 0.67
  17. Krishan R. Jethwa · 2 shared papers, 2026 · strength 0.65
  18. Abdelrahman M.G. Yousef · 3 shared papers, 2025–2026 · strength 0.55
  19. Mahmoud Yousef · 3 shared papers, 2025–2026 · strength 0.55
  20. Rebecca Anne Snyder · 3 shared papers, 2025–2026 · strength 0.55
  21. Ramez Kouzy · 4 shared papers, 2020–2024 · strength 0.51
  22. Dan Zhao · 3 shared papers, 2024–2025 · strength 0.51
  23. Ryan W. Huey · 3 shared papers, 2024–2026 · strength 0.51
  24. Joseph Abi Jaoude · 4 shared papers, 2020–2023 · strength 0.48
  25. Ahmed M. Elamir · 1 shared paper, 2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.